GlassScriptPhysician profile
Christopher Fennell
NPI 1437133535
$2,020.55
in general payments reported to CMS, 2019-2025
22 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $170 · 2021: $41.38 · 2022: $193 · 2023: $629 · 2024: $485 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.90 | 2021-2024 | |
| Alkermes, INC. | $267.73 | 2022-2025 | Lybalvi, Aristada |
| Allergan, INC. | $245.07 | 2019-2020 | |
| Axsome Therapeutics, INC. | $234.80 | 2022-2025 | Auvelity |
| Lundbeck LLC | $182.38 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.29 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $116.62 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $77.11 | 2024-2025 | Austedo Xr, Austedo Xr |
| Indivior INC. | $56.46 | 2020-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $48.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.63 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $31.13 | 2023 | Jornay Pm |
| Novo Nordisk INC | $20.17 | 2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.55 | 2024 | Trintellix |
| Pfizer INC. | $18.84 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.03 | 2024 | Mounjaro |
| Antares Pharma, INC. | $16.96 | 2023 | Nocdurna, Xyosted, Tlando |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2025 | Cobenfy |
| Bausch Health US, LLC | $14.50 | 2019 | |
| Merck Sharp & Dohme LLC | $14.43 | 2019 | |
| Grifols USA, LLC | $14.17 | 2023 | Prolastin-C Liquid |
| Acadia Pharmaceuticals INC | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fennell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.